Article

Korean FDA approves STAAR Surgical's TICL

Monrovia, CA—STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.

Monrovia, CA-STAAR Surgical Co. said it has received approval from the Korean Food and Drug Administration (KFDA) to market the STAAR Visian Toric lens (TICL) in South Korea.

The TICL is the first myopic ICL to receive KFDA approval, according to the company.

"This product will allow us to serve a broader population and further build our presence in our second-largest market for the myopic ICL," said David Bailey, president and chief executive officer of STAAR Surgical. The new market should provide a "meaningful increase" to the company's refractive business, he added.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
© 2025 MJH Life Sciences

All rights reserved.